Alks-5461 (Major Depressive Disorder) Market Size, Share, Trends and Forecasts to 2023

ALKS-5461 (Major Depressive Disorder) Market Size, Share, Trends,

Company Profiles, Demand, Insights, Analysis, Research, Report,

Opportunities, Segmentation and Forecast To 2023

Summary

Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide.

The MDD market is a crowded and competitive market, with more than 30 marketed products

available for the treatment of patients with MDD. The depression market is about to enter a

dynamic phase with imminent patent expiries for top selling products, such as Eli Lilly's

Cymbalta, and Otsuka/BMS's Abilify, along with the recent launch of the multimodal

antidepressant, Lundbeck/Takeda's Brintellix, in January 2014, and the potential introduction of

seven promising late-stage pipeline products into the market during the forecast period, from

2013 to 2023.

ALKS-5461 is being developed by Alkermes as an adjunctive treatment for MDD in patients

who have had an inadequate response to standard therapies. According to Alkermes, ALKS-5461

is expected to enter Phase III development during the first half of 2014. Following its very

successful Phase II trial, the FDA granted Fast Track status for ALKS-5461 in order to facilitate

its development and expedite its review by the regulatory authority (Alkermes, press release,

October 10, 2013).

Scope

- Overview of Major depressive disorder, including epidemiology, etiology, symptoms,

diagnosis, pathology and treatment guidelines as well as an overview on the competitive

landscape.

- Detailed information on ALKS-5461 including product description, safety and efficacy profiles

as well as a SWOT analysis.

- Sales forecast for ALKS-5461 for the top eight countries from 2013 to 2023.

- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and

Australia.

To Get More Details @ http://www.radiantinsights.com/research/alks-5461-majordepressive-disorder-forecast-and-market-analysis-to-2023

Reasons to buy

-...